 Connection
Sravani Gundarlapalli to Multiple Myeloma
This is a "connection" page, showing publications Sravani Gundarlapalli has written about Multiple Myeloma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.426 |
|
|
|
-
Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 12; 97(12):E451-E453.
Score: 0.074
-
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
Score: 0.072
-
Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198.
Score: 0.072
-
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 12 01; 106(12):3215-3218.
Score: 0.070
-
Yarlagadda N, Gundarlapalli S, Sharma S, Suelzer E, Abid MB, Abdallah AO, Schinke C, Atrash S, Mohan M. Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leuk Res. 2021 11; 110:106714.
Score: 0.069
-
Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
Score: 0.068
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|